


This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Previously Presented) Compounds of the formula I



in which

$X = N$  or  $CH$ ,

$R^1, R^2, R^3 =$  independently of one another  $OH, OA, CN, Hal, COR^4$  or  $CH_2R^4$ ,

$R^4 = OH, OA, NH_2, NHB$  or  $NB_2$ ,

$Q = CH_2$  or  $CO$ ,

$A, B =$  independently of one another straight-chain or branched alkyl or alkoxy

having 1 to 10 C atoms, alkenyl having 2 to 10 C atoms or alkoxyalkyl having

2 to 10 C atoms,


$m = 2, 3, 4, 5$  or  $6$  and

$n = 0, 1, 2, 3$  or  $4$ ,

or physiologically acceptable salts or stereoisomers thereof, including mixtures thereof in all ratios.


2. (Previously Presented) Compounds according to Claim 1 in which
- X = N,
- R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup> = independently of one another CN, OH, COR<sup>4</sup> or CH<sub>2</sub>R<sup>4</sup>,
- R<sup>4</sup> = OH, NH<sub>2</sub>, NHB or NHB<sub>2</sub>,
- Q = CH<sub>2</sub> or CO,
- B = alkyl having 1-6 C atoms,
- m = 4 and
- n = 0,
- or physiologically acceptable salts or stereoisomers thereof, including mixtures thereof in all ratios.

3. (Currently Amended) A compound ~~according to Claim 1 which is~~ of the formula
- a) 5-{4-[4-(5-cyano-2,3-dihydro-1H-indol-3-yl)butyl]piperazin-1-yl}benzofuran-2-carboxamide




or

- b) 5-{4-[4-(5-cyano-2-oxo-2,3-dihydro-1H-indol-3-yl)butyl]piperazin-1-yl}-benzofuran-2-carboxamide




or

c) 5-{4-(5-fluoro-2-oxo-2,3-dihydro-1H-indol-3-yl)butyl}piperazin-1-yl)-  
benzofuran-2-carboxamide or




4. (Previously Presented) Process for the preparation of compounds according to claim 1 or physiologically acceptable salts or stereoisomers thereof, comprising
- a) reacting a compound of the formula II, in which  $R^1$ ,  $R^2$ ,  $R^3$ , X, m and n have the meanings indicated in Claim 1,




with dimethyl sulfoxide and concentrated HCl,  
or

- b) reacting a compound of the formula III, in which  $R^1$ ,  $R^2$ , and  $n$  have the meanings indicated in Claim 1, and  $Y$  is a halogen or an alcohol provided with protecting groups,




with trifluoroacetic acid and triethylsilane and subsequently coupling with a compound of the formula IV, in which  $R^3$ ,  $X$  and  $n$  have the meanings indicated in Claim 1



and reacting with dimethyl sulfoxide and concentrated HCl  
or

- c) reacting a compound of the formula V, in which  $R^2$  and  $m$  have the meanings indicated in Claim 1 and  $Y$  is a halogen, or an alcohol provided with protecting groups,



with a dehydrating reagent and subsequently coupling with a compound of the formula IV, and reacting with dimethyl sulfoxide and concentrated HCl.

5. (Canceled)
6. (Previously Presented) Pharmaceutical composition comprising at least one compound according to claim 1 and/or physiologically acceptable salts or stereoisomers thereof, including mixtures thereof in all ratios, and a pharmaceutically acceptable carrier.
7. (Previously Presented) Pharmaceutical composition, according to Claim 6 comprising further excipients and/or adjuvants.
8. (Canceled).
9. (Previously Presented) Process for the preparation of a pharmaceutical composition, comprising bringing a compound according to claim 1 and/or one of its physiologically acceptable salts or stereoisomers, including mixtures thereof in all ratios, into a suitable dosage form together with a solid, liquid or semi-liquid excipient or adjuvant.
10. (Canceled)

11. (Canceled)

12. (Currently Amended) A method of achieving an anxiolytic, antidepressant, neuroleptic and/or antihypertonic effect and for treating migraine, ~~cerebral infarctions~~ or obsessive compulsive disorder, comprising administering to a host in need thereof an effective amount of a compound according to claim 1 and/or physiologically acceptable salts or stereoisomers thereof, including mixtures thereof in all ratios.

13. (Canceled)

14. (Canceled).

15. (Canceled).